Provides in-vitro fertilization (IVF) treatments to individuals and couples. Offers egg donation services for those who require donor eggs. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year). Red columns mark years that ended in a loss.
The gap is $4.1M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 12 buys and 2 sells. Management buying with its own money is usually read as a good sign.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.